{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:51:15Z","timestamp":1789386675609,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Janssen Biologics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Patients with ankylosing spondylitis (AS) are at increased risk of depression. This increased risk has been hypothesized to be solely secondary due to AS-related symptoms, or additionally due to a common inflammatory pathway. From a clinical perspective, it is important to know whether treatment with tumor necrosis factor alpha inhibitors reduces depressive symptoms, while from a pathophysiological point of view, it would be insightful to understand whether such an effect would be a direct result of reduced inflammation, the result of reduced AS-related symptoms, or both. The objective of this study was to evaluate the effect of infliximab on depressive symptoms in patients with AS in a randomized-controlled trial setting.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Data were retrieved from a subgroup of patients from the AS Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT). Patients were randomly allocated to infliximab (<jats:italic>n<\/jats:italic>\u2009=\u200916) or placebo (<jats:italic>n<\/jats:italic>\u2009=\u20097) until week 24, after which all received infliximab until week 54. Associations between treatment group and depressive symptoms, measured with the Center for Epidemiological Studies Depression scale (CES-D, range 0\u201360 (best-worst)) at baseline and over time, were explored with generalized estimating equations (GEE).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Mean CES-D score at baseline was 15.5 (SD 9.3) in the infliximab group and 17.3 (SD 5.7) in the placebo group. Twelve patients (52%) had a CES-D score\u00a0<jats:underline>&gt;<\/jats:underline>\u00a016, suggestive for clinical depression. After 24\u2009weeks, mean CES-D had decreased to 9.5 (SD 11.4) in the infliximab group, but was 18.0 (SD 6.9) in the placebo group. GEE revealed larger improvements in depressive symptoms (<jats:italic>B<\/jats:italic>\u2009=\u2009\u2212\u20096.63, 95%CI \u2212\u200913.35 to 0.09) and odds of possible depression (OR\u2009=\u20090.02, 95%CI 0.00 to 0.72) in the infliximab group, compared to the placebo group. Both associations largely disappeared when adjusted for self-reported disease activity and\/or physical function. Additional adjustment for C-reactive protein (CRP) did not change results.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Depressive symptoms are common in patients with AS and active disease. Infliximab improves these depressive symptoms in AS when compared to placebo by improving disease symptoms. We did not find an indication for a direct link between CRP-mediated inflammation and depressive symptoms.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>Trial registration (ASSERT): <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00207701\">NCT00207701<\/jats:ext-link>. Registered on September 21, 2005 (retrospectively registered).<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13075-020-02305-w","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T10:04:21Z","timestamp":1601373861000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT)"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-8547","authenticated-orcid":false,"given":"Casper","family":"Webers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Stolwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Schiepers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea","family":"Schoonbrood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"van Tubergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Landew\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"2305_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13075-018-1644-6","volume":"20","author":"S Zhao","year":"2018","unstructured":"Zhao S, Thong D, Miller N, et al. The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis. Arthritis Res Ther. 2018;20:140.","journal-title":"Arthritis Res Ther"},{"key":"2305_CR2","first-page":"395","volume":"66","author":"B Lowe","year":"2004","unstructured":"Lowe B, Willand L, Eich W, et al. Psychiatric comorbidity and work disability in patients with inflammatory rheumatic diseases. Psychosom Med. 2004;66:395\u2013402.","journal-title":"Psychosom Med"},{"key":"2305_CR3","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1093\/rheumatology\/kel115","volume":"45","author":"J Martindale","year":"2006","unstructured":"Martindale J, Smith J, Sutton CJ, et al. Disease and psychological status in ankylosing spondylitis. Rheumatology (Oxford). 2006;45:1288\u201393.","journal-title":"Rheumatology (Oxford)"},{"key":"2305_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nri.2015.5","volume":"16","author":"AH Miller","year":"2016","unstructured":"Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16:22\u201334.","journal-title":"Nat Rev Immunol"},{"key":"2305_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","volume":"70","author":"CL Raison","year":"2013","unstructured":"Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31\u201341.","journal-title":"JAMA Psychiatry"},{"key":"2305_CR6","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s00296-013-2671-x","volume":"33","author":"O Arisoy","year":"2013","unstructured":"Arisoy O, Bes C, Cifci C, et al. The effect of TNF-alpha blockers on psychometric measures in ankylosing spondylitis patients: a preliminary observation. Rheumatol Int. 2013;33:1855\u201364.","journal-title":"Rheumatol Int"},{"key":"2305_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00296-010-1616-x","volume":"32","author":"I Ertenli","year":"2012","unstructured":"Ertenli I, Ozer S, Kiraz S, et al. Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol Int. 2012;32:323\u201330.","journal-title":"Rheumatol Int"},{"key":"2305_CR8","first-page":"262","volume":"40","author":"ED Ersozlu-Bozkirli","year":"2015","unstructured":"Ersozlu-Bozkirli ED, Keskek SO, Bozkirli E, et al. The effect of infliximab on depressive symptoms in patients with ankylosing spondylitis. Acta Reumatol Port. 2015;40:262\u20137.","journal-title":"Acta Reumatol Port"},{"key":"2305_CR9","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/rheumatology\/kes142","volume":"51","author":"D van der Heijde","year":"2012","unstructured":"van der Heijde D, Braun J, Dougados M, et al. Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial. Rheumatology (Oxford). 2012;51:1894\u2013905.","journal-title":"Rheumatology (Oxford)"},{"key":"2305_CR10","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3899\/jrheum.141313","volume":"42","author":"M Dougados","year":"2015","unstructured":"Dougados M, Tsai WC, Saaibi DL, et al. Evaluation of health outcomes with etanercept treatment in patients with early nonradiographic axial spondyloarthritis. J Rheumatol. 2015;42:1835\u201341.","journal-title":"J Rheumatol"},{"key":"2305_CR11","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52:582\u201391.","journal-title":"Arthritis Rheum"},{"key":"2305_CR12","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286\u201391.","journal-title":"J Rheumatol"},{"key":"2305_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/014662167700100306","volume":"1","author":"LS Radloff","year":"1977","unstructured":"Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385\u2013401.","journal-title":"Appl Psychol Meas"},{"issue":"Suppl 11","key":"2305_CR14","doi-asserted-by":"publisher","first-page":"S454","DOI":"10.1002\/acr.20556","volume":"63","author":"KL Smarr","year":"2011","unstructured":"Smarr KL, Keefer AL. Measures of depression and depressive symptoms: Beck Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire-9 (PHQ-9). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S454\u201366.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2305_CR15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/anr.1780320808","volume":"32","author":"SJ Blalock","year":"1989","unstructured":"Blalock SJ, DeVellis RF, Brown GK, et al. Validity of the Center for Epidemiological Studies Depression Scale in arthritis populations. Arthritis Rheum. 1989;32:991\u20137.","journal-title":"Arthritis Rheum"},{"key":"2305_CR16","doi-asserted-by":"crossref","unstructured":"Ensel WM. 4 - Measuring Depression: The CES-D Scale. In: Lin N, Dean A, Ensel WM. Social Support, Life Events, and Depression. Orlando: Academic Press; 1986. p. 51\u201370.","DOI":"10.1016\/B978-0-12-450660-2.50011-2"},{"key":"2305_CR17","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281\u20135.","journal-title":"J Rheumatol"},{"key":"2305_CR18","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2307\/2531734","volume":"44","author":"SL Zeger","year":"1988","unstructured":"Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44:1049\u201360.","journal-title":"Biometrics"},{"key":"2305_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1023\/B:EJEP.0000036572.00663.f2","volume":"19","author":"JW Twisk","year":"2004","unstructured":"Twisk JW. Longitudinal data analysis. A comparison between generalized estimating equations and random coefficient analysis. Eur J Epidemiol. 2004;19:769\u201376.","journal-title":"Eur J Epidemiol"},{"key":"2305_CR20","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2019. URL: http:\/\/www.R-project.org."},{"key":"2305_CR21","unstructured":"Bouma J, Ranchor A, Sanderman R, et al. Het meten van symptomen bij depressie met de CES-D, een handleiding [Measurement of depressive symptoms with the CES-D, a manual]. Groningen, Noordelijk Centrum voor Gezondheidsvraagstukken, Rijksuniversiteit Groningen 19952\u201324."},{"key":"2305_CR22","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s00125-003-1124-6","volume":"46","author":"F Pouwer","year":"2003","unstructured":"Pouwer F, Beekman AT, Nijpels G, et al. Rates and risks for co-morbid depression in patients with type 2 diabetes mellitus: results from a community-based study. Diabetologia. 2003;46:892\u20138.","journal-title":"Diabetologia"},{"key":"2305_CR23","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1023\/A:1016673003237","volume":"9","author":"MJ Schroevers","year":"2000","unstructured":"Schroevers MJ, Sanderman R, van Sonderen E, et al. The evaluation of the Center for Epidemiologic Studies Depression (CES-D) scale: depressed and positive affect in cancer patients and healthy reference subjects. Qual Life Res. 2000;9:1015\u201329.","journal-title":"Qual Life Res"},{"key":"2305_CR24","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/acr.22249","volume":"66","author":"L Cordingley","year":"2014","unstructured":"Cordingley L, Prajapati R, Plant D, et al. Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66:861\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2305_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s13075-019-1995-7","volume":"21","author":"C Webers","year":"2019","unstructured":"Webers C, Vanhoof L, Leue C, et al. Depression in ankylosing spondylitis and the role of disease-related and contextual factors: a cross-sectional study. Arthritis Res Ther. 2019;21:215.","journal-title":"Arthritis Res Ther"},{"key":"2305_CR26","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/acr.23566","volume":"70","author":"M van Lunteren","year":"2018","unstructured":"van Lunteren M, Scharloo M, Ez-Zaitouni Z, et al. The impact of illness perceptions and coping on the association between back pain and health outcomes in patients suspected of having axial spondyloarthritis: data from the SPondyloArthritis Caught Early Cohort. Arthritis Care Res (Hoboken). 2018;70:1829\u201339.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2305_CR27","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1093\/rheumatology\/kez573","volume":"59","author":"SS Zhao","year":"2020","unstructured":"Zhao SS, Solomon DH, Goodson NJ. Comment on: comorbidity burden in axial spondyloarthritis: a cluster analysis: reply. Rheumatology (Oxford). 2020;59:692\u20133.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02305-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02305-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02305-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T23:54:53Z","timestamp":1632873293000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02305-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2305"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02305-w","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"17 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethics committee from the Maastricht University Medical Centre approved this substudy. All patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"225"}}